Pharmaceutical giant Pfizer has entered into a strategic research collaboration and licensing agreement with Enodia Therapeutics valued at upwards of…
Read More
Biotech Industry Bi-Weekly Digest: AI Integration, Genomic Breakthroughs, and Major Funding Initiatives Transform Therapeutics
The global biotechnology sector is undergoing a profound structural transformation, driven by the rapid convergence of artificial intelligence, high-throughput genomics,…
Read More
FDA Approves Asahi Kasei Therapeutics Hovilpri for Refractory Mucocutaneous Herpes Simplex Virus in Immunocompromised Adults
The United States Food and Drug Administration (FDA) has granted formal marketing approval for Hovilpri (pritelivir) 100mg tablets, developed by…
Read More
AI-Driven Oncology Pioneer Iambic Therapeutics Targets $135m Nasdaq IPO in Banner Year for Biotech Listings
Iambic Therapeutics, an oncology-focused biotechnology company recognized for its pioneering intersection of artificial intelligence and drug discovery, has officially set…
Read More
AstraZeneca and Daiichi Sankyo Join Forces with Summit Therapeutics in Strategic Clinical Partnership to Evaluate Novel Oncology Combinations
The oncology landscape is undergoing a significant strategic consolidation as major pharmaceutical players align their pipelines to maximize the therapeutic…
Read More
Atossa Therapeutics Unveils Shareholder Cash Reward Plan Tied to Rare Disease Priority Review Vouchers
Atossa Therapeutics has officially established a groundbreaking financial framework designed to directly reward its shareholders with a substantial cash payout…
Read More
MSD Strengthens Oncology Pipeline with Multi-Billion-Dollar Licensing Deal for Shanghai-Based SciBrunch Therapeutics KRAS Inhibitor SPR2015
In a strategic move to fortify its oncology portfolio against looming patent expirations, MSD—known as Merck & Co. in the…
Read More
AstraZeneca Deepens Oncology Footprint with $2bn Equity Investment in Summit Therapeutics to Advance Next-Generation Cancer Combinations
AstraZeneca has announced a landmark $2bn equity investment in Summit Therapeutics, marking a major strategic alignment between the pharmaceutical giants…
Read More
Virtual cells based on 4D lattice light-sheet microscopy predict mitochondrial responses to drugs, potentially accelerating therapeutics discovery
In the landscape of modern pharmaceutical research, the journey from identifying a potential drug candidate to conducting clinical trials remains…
Read More
FDA Public Hearing Examines the Future of Psychedelic Therapeutics and Balanced Regulatory Pathways
On September 14, the United States Food and Drug Administration (FDA) convened a landmark public hearing to address the evolving…
Read More
